Clinical Trial Update: Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 feasibility study evaluating a 60-minute rapid infusion rituximab protocol in patients with indolent or intermediate-grade B-cell malignancies complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancy
• Chronic Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Indolent B-cell Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Indolent or Intermediate Grade B-cell Malignancy | Phase 2 | Status: COMPLETED | Results posted: 2015-02-23